Stock ARYD ARYA SCIENCES ACQUISITION CORP IV
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases ARYA Sciences Acquisition Corp IV

Equities

ARYD

KYG316591083

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
11.33 USD -0.18% Intraday chart for ARYA Sciences Acquisition Corp IV +0.18% +3.94%
Mar. 29 ARYA Sciences Acquisition Corp IV Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Feb. 08 ARYA Sciences Acquisition Corp IV announced that it has received $1 million in funding from ARYA Sciences Holdings IV CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
ARYA Sciences Acquisition IV : Failure to Satisfy Listing Rule - Form 8-K
PU
Adagio Medical To List on Nasdaq Through Business Combination with ARYA Sciences Acquisition Corp IV, Enabling Further Commercial and Clinical Development of Innovative Cardiac Ablation Technologies
PR
ARYA Sciences Acquisition IV : New Financial Obligation - Form 8-K
PU
ARYA Sciences Acquisition IV : New Financial Obligation - Form 8-K
PU
ARYA Sciences Acquisition IV : New Financial Obligation - Form 8-K
PU
ARYA Sciences Acquisition Corp V will redeem its Class A Ordinary Shares and will not consummate an initial business combination
GL
ARYA SCIENCES ACQUISITION CORP IV Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)
AQ
ARYA Sciences Acquisition IV : Non-Reliance on Previously Issued Financial Report - Form 8-K
PU
ARYA SCIENCES ACQUISITION CORP IV : Non-Reliance on Previous Financials, Audits or Interim Review (form 8-K)
AQ
ARYA SCIENCES ACQUISITION CORP IV : Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)
AQ
ARYA SCIENCES ACQUISITION CORP IV : Other Events (form 8-K)
AQ
ARYA SCIENCES ACQUISITION CORP IV Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
AQ
ARYA SCIENCES ACQUISITION CORP IV : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregistered Sale of Equity Securities (form 8-K)
AQ
ARYA SCIENCES ACQUISITION CORP IV Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
AQ
ARYA SCIENCES ACQUISITION IV : AND AMICUS THERAPEUTICS, INC. MUTUALLY AGREE TO TERMINATE BUSINESS COMBINATION AGREEMENT WITH RESPECT TO THE ACQUISITION OF AMICUS’ GENE THERAPY BUSINESS DUE TO MARKET CONDITIONS - Form 8-K
PU
ARYA Sciences Acquisition Corp IV and Amicus Therapeutics, Inc. Mutually Agree to Terminate Business Combination Agreement With Respect to the Acquisition of Amicus’ Gene Therapy Business Due to Market Conditions
AQ
ARYA Sciences Acquisition IV : As discussed in Note 2 to the financial statement, the March 2, 2021 financial statement has been restated to correct a certain misstatement - Form 8-K/A
PU
Amicus Therapeutics : and ARYA Sciences Acquisition Corp IV Announce Formation of a Next-Generation Genetic Medicine Company, 'Caritas Therapeutics'
AQ
ARYA Sciences Acquisition IV : Business Combination of Amicus Gene Therapy Business with ARYA IV to Result in the Launch of Caritas Therapeutics, a New Independent, Publicly Traded Company with Expected ~$400M in Initial Funding (Form 8-K)
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ARYD Stock
  4. News ARYA Sciences Acquisition Corp IV
  5. Press Releases